Impact of treatment with TransCon PTH on Quality of Life, cognitive function, brain structure, and cerebral capillary bloodflow in patients with hypoparathyroidism

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523930-14-00

Enrollment

Registered

2026-04-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoparathyroidism

Brief summary

Difference in microvascular hemodynamic between PTH- and conventionally treated patients with chronic HypoPT

Detailed description

Correlation between cognitive impairment measured by neuropsychological assessment and capillary transit time heterogeneity, cortical blood volume and hemodynamic parameters., Status of cognitive function in PTH treated compared to conventional treated controls, Difference in groups in size of structures in the brain.

Interventions

DRUGAlfacalcidol Stada 1 micrograme capsule moi

DRUGYorvipath 168 micrograms/0.56 mL solution for injection in pre‑filled pen

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Difference in microvascular hemodynamic between PTH- and conventionally treated patients with chronic HypoPT	—

Secondary

Measure	Time frame
Correlation between cognitive impairment measured by neuropsychological assessment and capillary transit time heterogeneity, cortical blood volume and hemodynamic parameters., Status of cognitive function in PTH treated compared to conventional treated controls, Difference in groups in size of structures in the brain.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 21, 2026